Novo Nordisk Is Falling. A Rival Weight-Loss Drug Is on Way.
Novo Nordisk and Eli Lilly currently control 99% of the market, but their dominance may weaken as new entrants introduce ...
The biotech will commit $150 million to an alliance that hands it significant production capacity for a closely watched ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results